S100 proteins as potential predictive biomarkers of abatacept response in polyarticular juvenile idiopathic arthritis
Arthritis Research & Therapy · 2024
DOI: 10.1186/s13075-024-03347-0 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Arthritis Research & Therapy, 2024. Verfasst von Hermine I Brunner und 18 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cinc…. Hauptthemen laut MEDLINE: Abatacept, Arthritis, Juvenile, Biomarkers, Antirheumatic Agents. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAMS NIH HHS, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of the National Institutes of Health (NIH).
Abstract (Originalsprache)
Background
Juvenile idiopathic arthritis (JIA) comprises a heterogeneous group of conditions that can cause marked disability and diminished quality of life. Data on predictors of clinical response are insufficient to guide selection of the appropriate biologic agent for individual patients. This study aimed to investigate the propensity of S100A8/9 and S100A12 as predictive biomarkers of abatacept response in polyarticular-course juvenile idiopathic arthritis (pJIA).
Methods
Data from a phase 3 trial (NCT01844518) of subcutaneous abatacept in patients with active pJIA ( n = 219) were used in this exploratory analysis. Association between biomarker levels at baseline and improvements in JIA-American College of Rheumatology (ACR) criteria responses or baseline disease activity (measured by Juvenile Arthritis Disease Activity Score in 27 joints using C-reactive protein [JADAS27-CRP]) were assessed. Biomarker level changes from baseline to month 4 were assessed for disease outcome prediction up to 21 months.
Results
At baseline, 158 patients had available biomarker samples. Lower baseline S100A8/9 levels (≤ 3295 ng/mL) were associated with greater odds of achieving JIA-ACR90 (odds ratio [OR]: 2.54 [95% confidence interval (CI): 1.25–5.18]), JIA-ACR100 (OR: 3.72 [95% CI: 1.48–9.37]), JIA-ACR inactive disease (ID; OR: 4.25 [95% CI: 2.03–8.92]), JADAS27-CRP ID (OR: 2.34 [95% CI: 1.02–5.39]) at month 4, and JIA-ACR ID (OR: 3.01 [95% CI: 1.57–5.78]) at month 16. Lower baseline S100A12 levels (≤ 176 ng/mL) were associated with greater odds of achieving JIA-ACR90 (OR: 2.52 [95% CI: 1.23–5.13]), JIA-ACR100 (OR: 3.68 [95% CI: 1.46–9.28]), JIA-ACR ID (OR: 3.66 [95% CI: 1.76–7.61]), JIA-ACR90 (OR: 2.03 [95% CI: 1.07–3.87]), JIA-ACR100 (OR: 2.14 [95% CI: 1.10–4.17]), and JIA-ACR ID (OR: 4.22 [95% CI: 2.15–8.29]) at month 16. From baseline to month 4, decreases in S100A8/9 and S100A12 generally exceeded 50% among JIA-ACR90/100/ID responders.
Conclusion
Lower baseline levels of S100A8/9 and S100A12 proteins predicted better response to abatacept treatment than higher levels and may serve as early predictive biomarkers in pJIA. Decreases in these biomarker levels may also predict longer-term response to abatacept in pJIA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Rheumatology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, USA. Hermine.brunner@cchmc.org.
- Division of Rheumatology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
- Hospital México Americano, Guadalajara, CREA, Mexico.
- Pediatric Rheumatology Department, Hospital Sant Joan de Déu, Universitat de Barcelona, Barcelona, Spain.
- Ruben Cuttica MD, Pediatric Rheumatology, Hospital General de Niños Pedro de Elizalde, Buenos Aires, Argentina.
- Hamburg Centre for Pediatric and Adolescent Rheumatology, Schön Klinik Hamburg Eilbek, Hamburg, Germany.
Förderung
- NIAMS NIH HHS
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of the National Institutes of Health (NIH)
Zitieren
APA
Brunner, H. I., Schulert, G. S., Sproles, A., Thornton, S., Cornejo, G. V., Antón, J., Cuttica, R., Henrickson, M., Foeldvari, I., Kingsbury, D. J., Askelson, M., Liu, J., Mukherjee, S., Wong, R. L., Lovell, D. J., Martini, A., Ruperto, N., Grom, A. A., & Pediatric Rheumatology Collaborative Study Group (PRCSG) and the Paediatric Rheumatology International Trials Organisation (PRINTO) (2024). S100 proteins as potential predictive biomarkers of abatacept response in polyarticular juvenile idiopathic arthritis. Arthritis Research & Therapy. https://doi.org/10.1186/s13075-024-03347-0
Vancouver
Brunner HI, Schulert GS, Sproles A, Thornton S, Cornejo GV, Antón J, et al. S100 proteins as potential predictive biomarkers of abatacept response in polyarticular juvenile idiopathic arthritis. Arthritis Research & Therapy. 2024. doi:10.1186/s13075-024-03347-0
BibTeX
@article{Brunner2024,
author = {Brunner, Hermine I and Schulert, Grant S and Sproles, Alyssa and Thornton, Sherry and Cornejo, Gabriel Vega and Antón, Jordi and Cuttica, Ruben and Henrickson, Michael and Foeldvari, Ivan and Kingsbury, Daniel J and Askelson, Margarita and Liu, Jinqi and Mukherjee, Sumanta and Wong, Robert L and Lovell, Daniel J and Martini, Alberto and Ruperto, Nicolino and Grom, Alexei A and Pediatric Rheumatology Collaborative Study Group (PRCSG) and the Paediatric Rheumatology International Trials Organisation (PRINTO), Pediatric Rheumatology Collaborative Study Group (PRCSG) and the Paediatric Rheumatology International Trials Organisation (PRINTO)},
title = {S100 proteins as potential predictive biomarkers of abatacept response in polyarticular juvenile idiopathic arthritis},
journal = {Arthritis Research & Therapy},
year = {2024},
doi = {10.1186/s13075-024-03347-0}
}
EUVIMED